两种碳青霉烯类抗生素治疗重症肺炎的药物经济学分析

Pharmacoeconomics analysis on two kinds of carbapenems antibiotics in treatment of severe pneumonia

目的探讨两种碳青霉烯类抗生素（比阿培南和亚胺培南）治疗重症肺炎的成本效果。方法选择我院2012年9月-2015年9月期间收治的重症肺炎患者80例,随机将其分为观察组和对照组,每组40例。观察组给予比阿培南治疗,对照组给予亚胺培南治疗,疗程为10 d。评定两组治疗后的临床效果,确定治疗成本并比较两组成本效果。结果观察组总有效率为92.5%,与对照组总有效率（95.5%）近似,差异无统计学意义（P〉0.05）。观察组成本为4797元,对照组成本为9630元,观察组成本效果低于对照组,差异有统计学意义（P〈0.05）。结论比阿培南和亚胺培南治疗重症肺炎均可获得较好临床效果,但比阿培南成本效果低于亚胺培南。

Objective To discuss the cost-effectiveness of two kinds of carbapenems antibiotics（biapenem and imipenem） in treatment of severe pneumonia. Methods 80 patients with severe pneumonia treated in our hospital from September 2012 to September 2015 were selected and randomly divided into observation group and control group,each with 40 cases.Patients in the observation group were given biapenem,while pateints in the control group were given imipenem,both for 10 days.The clinical effects were assessed and treatment costs were confirmed in two groups.The cost-effectivenesses were compared. Results The overall response rates were similar in both groups,which was 92.5%in the observation group and 95.5% in the control group without significant difference（P〈0.05）.The cost was 4797 yuan in the observation group,while it was 9630 yuan in the control group.The cost-effectiveness was lower in the observation group than in the control group（P〈0.05）. Conclusion The clinical effects of biapenem and imipenem are favorable in treatment of severe pneumonia,and the cost-effectiveness of biapenem is lower than that of imipenem.